Literature DB >> 29107477

Contribution of Implanted, Genetically Modified Muscle Progenitor Cells Expressing BMP-2 to New Bone Formation in a Rat Osseous Defect.

Rodolfo E De La Vega1, Consuelo Lopez De Padilla2, Miguel Trujillo2, Nicholas Quirk2, Ryan M Porter3, Christopher H Evans4, Elisabeth Ferreira3.   

Abstract

Because muscle contains osteoprogenitor cells and has a propensity to form bone, we have explored its utility in healing large osseous defects. Healing is achieved by the insertion of muscle fragments transduced with adenovirus encoding BMP-2 (Ad.BMP-2). However, it is not known whether the genetically modified muscle contributes osteoprogenitor cells to healing defects or merely serves as a local source of BMP-2. This question is part of the larger debate on the fate of progenitor cells introduced into sites of tissue damage to promote regeneration. To address this issue, we harvested fragments of muscle from rats constitutively expressing GFP, transduced them with Ad.BMP-2, and implanted them into femoral defects in wild-type rats under various conditions. GFP+ cells persisted within defects for the entire 8 weeks of the experiments. In the absence of bone formation, these cells presented as fibroblasts. When bone was formed, GFP+ cells were present as osteoblasts and osteocytes and also among the lining cells of new blood vessels. The genetically modified muscle thus contributed progenitor cells as well as BMP-2 to the healing defect, a property of great significance in light of the extensive damage to soft tissue and consequent loss of endogenous progenitors in problematic fractures.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bone healing; cell fate; immunomodulation; muscle; osteoprogenitors; regenerative medicine

Mesh:

Substances:

Year:  2017        PMID: 29107477      PMCID: PMC5763073          DOI: 10.1016/j.ymthe.2017.10.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

1.  Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone.

Authors:  D S Musgrave; P Bosch; S Ghivizzani; P D Robbins; C H Evans; J Huard
Journal:  Bone       Date:  1999-06       Impact factor: 4.398

Review 2.  Regenerative medicine for the musculoskeletal system based on muscle-derived stem cells.

Authors:  Charley B Gates; Tharun Karthikeyan; Freddie Fu; Johnny Huard
Journal:  J Am Acad Orthop Surg       Date:  2008-02       Impact factor: 3.020

Review 3.  Skeletal muscle-resident MSCs and bone formation.

Authors:  Dario R Lemos; Christine Eisner; Claudia I Hopkins; Fabio M V Rossi
Journal:  Bone       Date:  2015-06-21       Impact factor: 4.398

4.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

5.  Mechanism of osteogenic induction by FK506 via BMP/Smad pathways.

Authors:  Fumitaka Kugimiya; Fumiko Yano; Shinsuke Ohba; Kazuyo Igawa; Kozo Nakamura; Hiroshi Kawaguchi; Ung-il Chung
Journal:  Biochem Biophys Res Commun       Date:  2005-10-14       Impact factor: 3.575

6.  Stem cell-derived endochondral cartilage stimulates bone healing by tissue transformation.

Authors:  Chelsea S Bahney; Diane P Hu; Aaron J Taylor; Federico Ferro; Hayley M Britz; Benedikt Hallgrimsson; Brian Johnstone; Theodore Miclau; Ralph S Marcucio
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

7.  Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release.

Authors:  Kate V Brown; Bing Li; Teja Guda; Daniel S Perrien; Scott A Guelcher; Joseph C Wenke
Journal:  Tissue Eng Part A       Date:  2011-04-03       Impact factor: 3.845

8.  In vitro gene transfer to chondrocytes and synovial fibroblasts by adenoviral vectors.

Authors:  Jean-Noel Gouze; Martin J Stoddart; Elvire Gouze; Glyn D Palmer; Steven C Ghivizzani; Alan J Grodzinsky; Christopher H Evans
Journal:  Methods Mol Med       Date:  2004

Review 9.  Tissue-specific stem cells: lessons from the skeletal muscle satellite cell.

Authors:  Andrew S Brack; Thomas A Rando
Journal:  Cell Stem Cell       Date:  2012-05-04       Impact factor: 24.633

10.  Advances in regenerative orthopedics.

Authors:  Christopher H Evans
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

View more
  5 in total

1.  Orthopaedic Gene Therapy: Twenty-Five Years On.

Authors:  Christopher H Evans; Steve C Ghivizzani; Paul D Robbins
Journal:  JBJS Rev       Date:  2021-08-26

2.  A Transgenic Rat for Noninvasive Assessment of Chondrogenesis in Vivo.

Authors:  Elisabeth Ferreira; Landon B Gatrell; Luke Childress; Hong Wu; Ryan M Porter
Journal:  Cartilage       Date:  2021-11-22       Impact factor: 3.117

Review 3.  Gene therapy for bone healing: lessons learned and new approaches.

Authors:  Rodolfo E De la Vega; Aysegul Atasoy-Zeybek; Joseph A Panos; Martijn VAN Griensven; Christopher H Evans; Elizabeth R Balmayor
Journal:  Transl Res       Date:  2021-05-05       Impact factor: 10.171

4.  Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.

Authors:  Rodolfo E De La Vega; Martijn van Griensven; Wen Zhang; Michael J Coenen; Christopher V Nagelli; Joseph A Panos; Carlos J Peniche Silva; Johannes Geiger; Christian Plank; Christopher H Evans; Elizabeth R Balmayor
Journal:  Sci Adv       Date:  2022-02-16       Impact factor: 14.136

5.  Epigallocatechin-3-Gallate Ameliorates Glucocorticoid-Induced Osteoporosis of Rats in Vivo and in Vitro.

Authors:  Shengye Liu; Liyu Yang; Shuai Mu; Qin Fu
Journal:  Front Pharmacol       Date:  2018-05-09       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.